Sanofi (France)
NEWS
Sanofi and Regeneron halted a Phase III study of its checkpoint inhibitor Libtayo as a monotherapy treatment for advanced or metastatic non-small cell lung cancer due to early signs of significant improvement in overall survival.
Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look.
David Loew, head of Sanofi Pasteur, said U.S. approval of the vaccine is an important milestone in the fight against meningococcal meningitis, a serious global health challenge that can be fatal within 24 hours.
The company said the treatment significantly reduced disease activity as measured by magnetic resonance imaging.
Here’s a look at what’s on the U.S. Food and Drug Administration’s schedule for the next two weeks.
The two companies will evaluate a smartphone-based self-testing solution for COVID-19, using Luminostics’ innovative technology and Sanofi’s clinical research abilities.
It’s likely that more companies and universities will add additional assets as time goes on.
The two companies are eying the second half of this year to begin clinical trials on their combined project and, if the vaccine meets expectations, the companies said it could be available for use in the second half of 2021.
Many people have lost their jobs and, as a result, their insurance. That can be daunting enough, but for those who need life-saving drugs such as insulin, the situation is magnified.
JOBS
IN THE PRESS